Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

November 29, 2018 Group News

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn’s, Bronchopulmonary dysplasia, Epilepsy and Stroke

Amsterdam, The Netherlands – 29 November 2018
read more

ESPERITE (ESP): financial results for 2017 are published.

November 23, 2018 Financial Reports

ESPERITE N.V. (Euronext: ESP, “Esperite”, “the Company” or “the Group”) has published today its Annual Report for the year ended 31 December 2017. The 2017 Annual Report is now available on the Company’s website www.esperite.com.

  • CryoSave’s EBITDA turned positive from € -0.7 million to € 1.3 million.
  • Genoma with AGAATA made strong technological progress despite the liquidation of the Swiss Genoma SA. AGAATA in its latest 3rd version is the state of the art in Genetic Diagnostic technology.
  • The Cell Factory, who had a busy year initiating the first-in-man clinical trials in treatment of Crohn’s disease with EVs technology, obtained its patent granted in China, Canada and Europe for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology. The Cell Factory received European funding to develop the 2nd generation EVs drug for treatment of Stroke.
  • Consolidated EBITDA improved from € -5.0 million to € -4.5 million. This improvement is in line with the improvement of operating cash flow before working capital movements which improved from € -5.0 million to € -4.4 million. As a result of the investments by European Select Growth Opportunities Fund the cash position increased by € 0.3 million.
  • Esperite’s consolidated revenue decreased by 37% to € 16.6 million however the gross margin increased by 10% from 56% to 66% as a result of termination of several distribution agreements with partners in countries which were loss making or cash flow negative. Furthermore Esperite has redefined its geographic footprint, optimized the teams, adjusted the balance between B2B and B2C and brought in sophisticated commercial tools.
  • Consolidated result amounted to € -12.9 million compared to € -8.5 million. This decrease is mainly due to impairment losses amounting to € 5.6 million in 2017 compared to € 1.0 million in 2016.
  • The results of the not consolidated interests of the Company contributed € 0.7 million positively to the 2017 results compared to a negative contribution amounting to € 0.3 in 2016.
  • Although liquidity remains an issue for the Company management feels confident about the going concern as a result of additional financing which has been secured in 2018 amounting to € 5.0 million from European Select Growth Opportunities Fund with a duration of 2 years. This financing is subject to certain conditions.

Amsterdam, The Netherlands – 23 November 2018

read more

Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia.

November 6, 2018 Group News

Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia.

Amsterdam, The Netherlands – 06 November 2018
read more

ESPERITE N.V. (ESP) WITH CRYOSAVE READY TO STORE MORE THAN A MILLION SAMPLES IN ITS NEW DESIGNED CRYOSTORAGE FACILITY IN GENEVA.

September 13, 2018 Group News

CryoSave has fully equipped this new safe and secure sample storage BioBank in its state-of-the-art central laboratory in Geneva, Switzerland especially designed for optimal cryopreservation of all biological samples and therefore provide peace of mind to institutional clients and families.

Amsterdam, The Netherlands – 13 September 2018
read more

ESPERITE N.V. (ESP) SELLS ITS STAKE IN CRYOSAVE SOUTH AFRICA TO GO LIFE HEALTHCARE (GLI).

July 2, 2018 Group News

ESPERITE N.V. (ESP) SELLS ITS STAKE IN CRYOSAVE SOUTH AFRICA TO GO LIFE HEALTHCARE (GLI).

CryoSave in its joint venture with Ecsponent (ECS) at equal participation have sold 100% of their stake for ZAR 50,000,000 (Fifty Million South African Rand).

As a leading stem cells bank, CryoSave SA will continue to as-sist Go Life Healthcare with its long-established professionalism and expertise.

Amsterdam, The Netherlands – 02 July 2018
read more

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

May 17, 2018 Group News

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

Amsterdam, The Netherlands – 17 May 2018

read more

Page 1 of 1012345...10...Last »